FDA Brief

Warning letters Food

FDA warning letter to

American Pharma Mfg. Inc.

High riskIssued Aug 4Posted Sep 29Human Foods Program

FDA warns American Pharma Mfg. of serious dietary supplement manufacturing violations at its Ontario, CA facility.

What happened

FDA inspected American Pharma Mfg. Inc.'s Ontario, CA dietary supplement facility from March 16-27, 2026 and gave the company a Form FDA 483, a list of inspection findings. FDA found violations of current good manufacturing practice (CGMP), the rules for how dietary supplements must be made, including unqualified quality-control staff, sanitation and pest problems, missing specifications and batch records, and metal detector failures. The company responded April 14 and 17, 2026, but FDA said the responses did not show adequate corrections.

What FDA found

  1. People doing quality-control work were not qualified or knowledgeable about the applicable requirements.

    21 CFR 111.12(b)
  2. The plant was not kept clean, sanitary, and in good repair; investigators saw powder buildup, unknown residue on floors and walls, and holes and temporary patches in wall corners.

    21 CFR 111.15(b)
  3. Cleaning chemicals were stored near ingredients and product, a warehouse exit door had a pest-entry gap, and liquid waste was kept in uncovered and unsanitary containers.

    21 CFR 111.15(c)(3), (d)(2), (f)(2)
  4. The company did not set written requirements for ingredient identity and contaminants, or for finished product identity, purity, strength, composition, and contaminants.

    21 CFR 111.70(b), (e)
  5. The company did not prepare a batch production record, a record of each manufactured batch, for every batch and left required details out of other batch records.

    21 CFR 111.255(a), 111.260(f), 111.260(j)
  6. The metal detector was not properly connected, failed to detect test pieces, and was not checked or documented properly.

    21 CFR 111.365(i)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, explain how recurrence will be prevented, and provide related documentation. If corrections cannot be completed within that time, the company must state the reason and the time frame for doing so.

Who should pay attention

  • brands that use this company as a contract manufacturer
  • dietary supplement distributors and retailers sourcing its products
  • quality teams at other dietary supplement manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk